AJP - Regulatory, Integrative and Comparative Physiology, Vol 262, Issue 3 395-R399, Copyright © 1992 by American Physiological Society

ARTICLES

Comparison of renal actions of urodilatin and atrial natriuretic peptide

D. A. Hildebrandt, H. L. Mizelle, M. W. Brands and J. E. Hall
Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson 39216.

A 32-amino acid atrial natriuretic peptide (ANP)-like peptide, putatively synthesized by the kidney, has recently been isolated from human urine. This peptide, urodilatin (Uro), is structurally similar to the 28-amino acid ANP, suggesting that they might have similar actions on renal fluid and electrolyte excretion. The purpose of this study was to characterize the direct renal actions of low doses of Uro infusion and to compare them with the effects of equimolar intrarenal infusions of either ANP or the 24-amino acid atriopeptin III (AP III). Synthetic Uro was infused into the renal artery of pentobarbital sodium-anesthetized mongrel dogs (n = 8) at 0.14, 0.28, and 1.43 pmol.kg-1.min-1 while renal perfusion pressure was servo-controlled at 100 mmHg. Uro infusion at 1.43 pmol.kg-1.min-1 increased sodium excretion from an average control of 57.4 +/- 10.1 to 159.0 +/- 24.4 mueq/min. Uro infusion at the highest dose also increased potassium excretion (28.0 +/- 4.5 vs. 40.4 +/- 7.4 mueq/min), chloride excretion (56 +/- 11 vs. 155 +/- 22 mueq/min), and urine volume (0.54 +/- 0.12 vs. 1.22 +/- 0.25 ml/min). Fractional lithium excretion, a marker for proximal tubular sodium reabsorption, was not altered by Uro infusion, nor were urinary guanosine 3',5'-cyclic monophosphate excretion, glomerular filtration rate, or effective renal plasma flow changed. Equimolar infusions of these low doses of either alpha human ANP (n = 6) or AP III (n = 8) had no effect on any of the measured variables. Thus, within the range of doses used in this study, Uro was a more effective natriuretic and diuretic agent than either ANP or AP III.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				H. H. Chen, A. Cataliotti, J. A. Schirger, F. L. Martin, and J. C. Burnett Jr. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2005; 288(5): R1093 - R1097. [Abstract] [Full Text] [PDF]

				R. T. Schermuly, N. Weissmann, B. Enke, H. A. Ghofrani, W. G. Forssmann, F. Grimminger, W. Seeger, and D. Walmrath Urodilatin, a Natriuretic Peptide Stimulating Particulate Guanylate Cyclase, and the Phosphodiesterase 5 Inhibitor Dipyridamole Attenuate Experimental Pulmonary Hypertension . Synergism upon Coapplication Am. J. Respir. Cell Mol. Biol., August 1, 2001; 25(2): 219 - 225. [Abstract] [Full Text] [PDF]

				M. Heringlake, K. Wagner, J. Schumacher, and H. Pagel Urinary excretion of urodilatin is increased during pressure natriuresis in the isolated perfused rat kidney Am J Physiol Renal Physiol, September 1, 1999; 277(3): F347 - F351. [Abstract] [Full Text] [PDF]

				M. H. Bestle, N. V. Olsen, P. Christensen, B. V. Jensen, and P. Bie Cardiovascular, endocrine, and renal effects of urodilatin in normal humans Am J Physiol Regulatory Integrative Comp Physiol, March 1, 1999; 276(3): R684 - R695. [Abstract] [Full Text] [PDF]

				W. Schmidt, A. Bub, M. Meyer, T. Weiss, G. Schneider, N. Maassen, and W. G. Forssmann Is urodilatin the missing link in exercise-dependent renal sodium retention? J Appl Physiol, January 1, 1998; 84(1): 123 - 128. [Abstract] [Full Text] [PDF]

				J. Sehested, B. Wacker, W.-G. Forssmann, and E. Schmitzer NATRIURESIS AFTER CARDIOPULMONARY BYPASS: RELATIONSHIP TO URODILATIN, ATRIAL NATRIURETIC FACTOR, ANTIDIURETIC HORMONE, AND ALDOSTERONE J. Thorac. Cardiovasc. Surg., October 1, 1997; 114(4): 666 - 671. [Abstract] [Full Text]